Dyne Therapeutics (NASDAQ:DYN) Director Buys $36,420.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner purchased 2,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average cost of $18.21 per share, with a total value of $36,420.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at $364,200. This trade represents a 11.11% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Dyne Therapeutics Trading Up 4.1%

Shares of NASDAQ DYN opened at $19.33 on Friday. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The stock has a market cap of $3.20 billion, a P/E ratio of -6.00 and a beta of 1.08. The firm has a 50-day moving average of $18.29 and a 200 day moving average of $18.31. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the previous year, the firm earned ($1.05) EPS. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics in the 1st quarter worth approximately $26,000. Chung Wu Investment Group LLC bought a new stake in shares of Dyne Therapeutics in the third quarter worth approximately $30,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth approximately $51,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth approximately $84,000. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DYN has been the subject of a number of recent research reports. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Chardan Capital restated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research note on Monday, March 9th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Sanford C. Bernstein boosted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.